Cell-cell interactions in synovitis: Interactions between T lymphocytes and synovial cells
© Current Science Ltd 2000
Received: 17 April 2000
Accepted: 23 April 2000
Published: 18 July 2000
Skip to main content
© Current Science Ltd 2000
Received: 17 April 2000
Accepted: 23 April 2000
Published: 18 July 2000
Mechanisms whereby T lymphocytes contribute to synovial inflammation in rheumatoid arthritis are poorly understood. Here we review data that indicate an important role for cell contact between synovial T cells, adjacent macrophages and fibroblast-like synoviocytes (FLS). Thus, T cells activated by cytokines, endothelial transmigration, extracellular matrix or by auto-antigens can promote cytokine, particularly TNFα, metalloproteinase production by macrophages and FLS through cell-membrane interactions, mediated at least through β-integrins and membrane cytokines. Since soluble factors thus induced may in turn contribute directly to T cell activation, positive feedback loops are likely to be created. These novel pathways represent exciting potential therapeutic targets.
The elucidation of pathways by which T lymphocytes might contribute to synovial inflammation in rheumatoid arthritis (RA) has proved elusive. Thus, mechanisms by which synovial T cells are activated, and subsequently effect articular inflammation, remain incompletely understood. Moreover, the magnitude and nature of such effector pathways might not be constant over time or in different individuals. The predominance of macrophage-derived cytokines, particularly tumour necrosis factor (TNF)-α in the hierarchy of synovial inflammation has been clearly demonstrated in several recent clinical studies [1*]. Those factors that in turn promote such macrophage activation could represent effective therapeutic targets, but are currently ill-defined. This brief review will explore the hypothesis that a significant proportion of such pro-inflammatory activity might reside in synovial T cells through their capacity to modulate inflammation by cell-cell contact.
Data from animal models, recognised HLA associations and the clinical efficacy of T cell targeted therapies implicate T cells in promoting RA synovitis [2,3]. Empirically, synovial T cells might drive inflammation through the release of inflammatory mediators, particularly cytokines, or through pathways dependent on cell contact. Several reports indicate that synovial CD4+, CD45RO+ T cells are predominantly of 'type 1' polarity [4–10]. Synovial T cell clones are usually of Th1 phenotype. Up to 80% of synovial T cells are CCR5+; when stimulated with mitogen they predominantly express interferon (IFN)-γ but not interleukin (IL)-4, as assessed by ELISPOT or intracellular fluorescence-activated cell sorting. T cell derived cytokines that can be detected in synovium, albeit at low levels, are of Th1 type and include IFN-γ and IL-17. Using double specific antibodies, we recently detected spontaneous IFN-γ production by less than 1% of RA synovial T cells ex vivo (JA Gracie and IB McInnes, unpublished data), commensurate with the foregoing immunohistochemical observations. A priori, therefore, it seems unlikely that such cytokine output by T cells could fully explain the extensive and perpetual synovial inflammation apparent in RA.
T cells and macrophages lie in juxtaposition within and adjacent to cellular aggregates in the synovial membrane, providing for reciprocal cellular cross-talk. Such interactions can effectively activate T cells through the local release of cytokines (eg IL-12, IL-18), through co-stimulation (eg via pathways dependent on CD28, CD154 or CD47), and/or through the presentation of putative auto-antigens [11–13]. However, it has recently become clear that T cells in turn might be stimulatory to adjacent macrophages. Dayer and colleagues have provided elegant results demonstrating that T lymphocytes can modulate the activity of a variety of cell types through cell contact [14*,15*]. However, most such studies have employed mitogen-activated T cells. We recently demonstrated that freshly isolated, paraformaldehyde-fixed T-lymphocyte-enriched populations from synovial fluid might induce TNF-α production directly by blood or synovial macrophages through pathways dependent on cell contact [16*], without additional exogenous stimulation. Moreover, this property can be sustained or enhanced in vitro by the addition of cytokines that activate T cells, such as IL-15 [16*]. These observations indicate that a fundamental property of synovial T cells might be the activation of adjacent cells mediated by cell contact.
Studies investigating blood-derived lymphocyte-macrophage interactions clearly indicate that secretory activity arising from cell contact extends beyond TNF-α to include numerous cytokines such as IL-1β and IL-12, and cytokine inhibitors such as TNF receptor p75 and IL-1RA [14*,20, 21*,22]. We have also recently demonstrated that synovial macrophages consistently release low levels of IL-15 after contact with cytokine-activated synovial or blood-derived T cells (unpublished data). The production of matrix metalloproteinase (MMP), but not of tissue inhibitor of MMP (TIMP)1, by THP-1 cells and blood-derived macrophages might also be induced after contact with T cells . The relative role of cell contact and soluble factors apparently vary for the production of different cytokines. During investigations of the pro-inflammatory activities of T cells and macrophages in glomerular inflammation, we recently defined discrete requirements for cell contact and for soluble factors during the induction of expression of cytokines, chemokines and adhesion molecules by mesangial or renal tubular epithelial cells [24,25]. For example, whereas either cell-contact or soluble factors induced monocyte chemotactic protein-1 (MCP-1) and IP-10, RANTES production by RTEC was dependent exclusively on contact. Similar studies are required to characterise such regulatory diversity within RA synovial membrane.
The precise membrane ligands implicated in interactions between synovial T cells and macrophages are currently unclear. Co-incubation with neutralising antibodies against LFA-1 (lymphocyte function associated antigen-1), intercellular cell-adhesion molecule-1 (ICAM-1) and CD69 effectively suppresses synovial T cell induced activation of macrophages [15*,16*]. By extension from studies with T cells derived from peripheral blood, CD11b, CD40L and CD45 might also be implicated [21*,22]. Membrane-bound cytokines, particularly IL-1α, TNF-α and IFN-γ, clearly represent logical additional candidate molecules [14*]. It is also of interest that membrane-bound IL-15 has recently been described in blood-derived monocytes . However, such studies are not straightforward because steric hindrance by antibodies can confound, and the formal characterisation of critical pathways remains elusive. Similarly, the signalling consequences within macrophages after T cell contact have been little studied. These might not be easily predicted. For example, a recent comparison of TNF-α synthesis induced by LPS and CD45 in monocytes revealed the discrete use of phosphoinositide 3-kinase and the nuclear factor NF-κB, but common use of p38 mitogen-activated protein kinase (MAPK) pathways by these diverse stimuli . Thus, the precise mechanisms by which T cells are activated, and the relative contribution of subsequent cell contact in comparison with macrophage activation mediated by soluble factors, might profoundly influence signalling events in synovial macrophages. Such detail will probably have important implications in the design of future targeted therapies.
The significance of the predominant Th1 polarity of synovial T cells in the context of cognate interactions is unclear. Recent studies indicate that cytokine-activated Th1 cells exhibit greater potential to enhance the expression of monocyte IL-1β through cell contact than do Th2 cells [21*]. This might in part be mediated through CD154-CD40 interactions. In contrast, Th1 and Th2 cells induce similar IL-10 production, whereas Th2 cells are more efficient in inducing IL-1RA synthesis . We recently described the expression of IL-18 in RA synovial membrane, which together with IL-12 and IL-15 probably sustains a Th1 phenotype in synovial T cells . In the absence of high levels of IFN-γ production in situ, cognate interactions involving synovial Th1 cells might be of critical importance. Studies addressing this important issue are under way in several laboratories.
Cell contact between T lymphocytes and fibroblast-like synoviocytes (FLS) is a further important area of interest. Early studies demonstrated that cytokine-activated FLS bind T cells through pathways that are dependent on at least ICAM-1 . The synthesis of FLS collagen types I and III is downregulated at the transcriptional level by cell contact with mitogen-activated T cells or membrane preparations derived from T cells . These effects are not tissue-specific because similar effects can be mediated on dermal fibroblasts. Direct contact with blood-derived activated T cells, or synovial CD4+ and CD8+ T cell clones, induces the production of MMP and prostaglandin by FLS . In contrast, TIMP1 is only briefly upregulated in this system. Membrane-bound cytokines, including TNF-α and IL-1α, but not CD69, CD154 or CD11b, seem crucial to such interactions between T cells and FLS . The capacity of FLS to respond in co-cultures might be enhanced by TGF-β. Moreover, because FLS activated by IL-1β and TNF-α express in turn cytokines capable of T cell activation, including IL-7, IL-15 and IL-18 [11,16*,31], it is likely that local positive feedback loops, similar to those described above for T cells and monocytes, might be generated. Together these results suggest that interactions between T cells and FLS could contribute significantly to the extra-cellular matrix dysregulation characteristic of RA.
The foregoing discussion has focused on 'bystander' cytokine-mediated T cell activation. This provides for TCR-independent activation, by which polyclonal memory T cell populations can contribute within an inflammatory lesion, irrespective of local antigen expression. This hypothesis does not preclude a role for T cell populations driven by autoantigens . Several recent reports have identified oligoclonal T cell expansion in RA synovial membrane, particularly among CD4+, CD28- cells , although molecular targets remain unknown. However, whether such expanded antigen-specific T cell subsets can contribute in vivo to chronic inflammation in a quantitatively important manner through cell contact is as yet unclear.
The fundamental importance of T cell activation after interactions with endothelial cells has long been recognised. CD45RO+ T cells from peripheral blood exhibit intrinsic migratory potential and are further activated during transmigration through endothelia [34,35]. This can be demonstrated directly by using the human synovium-SCID (severe combined immunodeficiency) mouse model in which human T cell migration is critically dependent on the expression of adhesion molecules and cytokines on endothelial cells . This model provides further powerful evidence of a central role for polyclonal T cells in promoting synovial inflammation in vivo, because T cell depletion mediated by anti-CD2 within synovial grafts leads to the suppression of IL-1β, TNF-α and IL-15 levels and of MMP expression. The administration of T cells leads in turn to replenishment of these cytokine activities [37*].
The therapeutic success of TNF-α blockade illustrates the potential of selective immune pathway targeting in vivo. The foregoing results strongly suggest that T cells might promote the production of pro-inflammatory cytokines and MMP through cell-cell interactions within the synovial membrane (Fig. 1). It is intriguing that the response after anti-CD4 treatment is correlated with the proportion of synovial CD4+ T cells coated by antibody . Moreover, the mechanism for action of anti-TNF-α antibodies, might potentially include the targeting of T cells through recognition of membrane TNF-α. Thus, therapeutic strategies that target both TNF-α and T cells, or critical pathways dependent on cell contact deserve consideration.
intercellular cell-adhesion molecule-1
T cell receptor
tissue inhibitor of MMP
tumour necrosis factor
We thank the Arthritis Research Campaign (UK), The Wellcome Trust, The Scottish Chief Scientist Office, and the Medical Research Council (UK) for their invaluable support.